Europe RNAi Therapeutics Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. Europe RNAi Therapeutics Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. Europe RNAi Therapeutics Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. Europe RNAi Therapeutics Market Regional Analysis

6.2 Europe RNAi Therapeutics Market Revenue 2017-2027 (US$ Million)

6.3 Europe RNAi Therapeutics Market Forecast Analysis

7. Europe RNAi Therapeutics Market Analysis – by Molecule Type

7.1 Small Interfering RNAs

7.1.1 Overview
7.1.2 Small Interfering RNAs: Europe RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

7.2 MicroRNA

7.2.1 Overview
7.2.2 MicroRNA: Europe RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

8. Europe RNAi Therapeutics Market Analysis – by Application

8.1 Genetic Disorders

8.1.1 Overview
8.1.2 Genetic Disorders: Europe RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

8.2 Oncology

8.2.1 Overview
8.2.2 Oncology: Europe RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

8.3 Neurodegenerative Disorders

8.3.1 Overview
8.3.2 Neurodegenerative Disorders: Europe RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

8.4 Cardiovascular

8.4.1 Overview
8.4.2 Cardiovascular: Europe RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

8.5 Respiratory Disorders

8.5.1 Overview
8.5.2 Respiratory Disorders: Europe RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

8.6 Infectious Diseases

8.6.1 Overview
8.6.2 Infectious Diseases: Europe RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

8.7 Renal Diseases

8.7.1 Overview
8.7.2 Renal Diseases: Europe RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

9. Europe RNAi Therapeutics Market Analysis – by Route of Administration

9.1 Intradermal Injections

9.1.1 Overview
9.1.2 Intradermal Injections: Europe RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

9.2 Pulmonary Delivery

9.2.1 Overview
9.2.2 Pulmonary Delivery: Europe RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

9.3 Intravenous Injections

9.3.1 Overview
9.3.2 Intravenous Injections: Europe RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

9.4 Intraperitoneal Injections

9.4.1 Overview
9.4.2 Intraperitoneal Injections: Europe RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

10. Europe RNAi Therapeutics Market Analysis – by End User

10.1 Diagnostic Laboratories

10.1.1 Overview
10.1.2 Diagnostic Laboratories: Europe RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

10.2 Research and Academic Laboratories

10.2.1 Overview
10.2.2 Research and Academic Laboratories: Europe RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

10.3 Hospitals

10.3.1 Overview
10.3.2 Hospitals: Europe RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)

11. Europe RNAi Therapeutics Market – Europe Analysis

11.1 Overview

11.2 Europe

11.2.1 Europe RNAi Therapeutics Market Breakdown, by Key Country, 2020 and 2027 (%)
11.2.1.1 Europe RNAi Therapeutics Market – Revenue and Forecast Analysis – by Country
11.2.1.1 UK: Europe RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

11.2.1.1.1 UK: Europe RNAi Therapeutics Market Breakdown, by Molecule Type
11.2.1.1.2 UK: Europe RNAi Therapeutics Market Breakdown, by Application
11.2.1.1.3 UK: Europe RNAi Therapeutics Market Breakdown, by Route of Administration
11.2.1.1.4 UK: Europe RNAi Therapeutics Market Breakdown, by End User

11.2.1.2 Germany: Europe RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

11.2.1.2.1 Germany: Europe RNAi Therapeutics Market Breakdown, by Molecule Type
11.2.1.2.2 Germany: Europe RNAi Therapeutics Market Breakdown, by Application
11.2.1.2.3 Germany: Europe RNAi Therapeutics Market Breakdown, by Route of Administration
11.2.1.2.4 Germany: Europe RNAi Therapeutics Market Breakdown, by End User

11.2.1.3 France: Europe RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

11.2.1.3.1 France: Europe RNAi Therapeutics Market Breakdown, by Molecule Type
11.2.1.3.2 France: Europe RNAi Therapeutics Market Breakdown, by Application
11.2.1.3.3 France: Europe RNAi Therapeutics Market Breakdown, by Route of Administration
11.2.1.3.4 France: Europe RNAi Therapeutics Market Breakdown, by End User

11.2.1.4 Russia: Europe RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

11.2.1.4.1 Russia: Europe RNAi Therapeutics Market Breakdown, by Molecule Type
11.2.1.4.2 Russia: Europe RNAi Therapeutics Market Breakdown, by Application
11.2.1.4.3 Russia: Europe RNAi Therapeutics Market Breakdown, by Route of Administration
11.2.1.4.4 Russia: Europe RNAi Therapeutics Market Breakdown, by End User

11.2.1.5 Italy: Europe RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

11.2.1.5.1 Italy: Europe RNAi Therapeutics Market Breakdown, by Molecule Type
11.2.1.5.2 Italy: Europe RNAi Therapeutics Market Breakdown, by Application
11.2.1.5.3 Italy: Europe RNAi Therapeutics Market Breakdown, by Route of Administration
11.2.1.5.4 Italy: Europe RNAi Therapeutics Market Breakdown, by End User

11.2.1.6 Rest of Europe: Europe RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

11.2.1.6.1 Rest of Europe: Europe RNAi Therapeutics Market Breakdown, by Molecule Type
11.2.1.6.2 Rest of Europe: Europe RNAi Therapeutics Market Breakdown, by Application
11.2.1.6.3 Rest of Europe: Europe RNAi Therapeutics Market Breakdown, by Route of Administration
11.2.1.6.4 Rest of Europe: Europe RNAi Therapeutics Market Breakdown, by End User

12. Competitive Landscape

12.1 Heat Map Analysis

12.2 Company Positioning and Concentration

13. Industry Landscape

13.1 Overview

13.2 Market Initiative

13.3 Partnerships and Collaborations

13.4 Other Developments

14. Company Profiles

14.1 Sanofi

14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments

14.2 GlaxoSmithKline plc

14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments

14.3 Silence Therapeutics

14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments

14.4 Alnylam Pharmaceuticals, Inc

14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments

14.5 Arrowhead Pharmaceuticals, Inc

14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments

15. Appendix

15.1 About Business Market Insights

15.2 List of Abbreviations

Europe RNAi Therapeutics Market